The epidemiology of vancomycin resistant enterococci

Current Opinion in Infectious Diseases

Volumn 12, Issue 6, 1999, Pages 537-541

  Goossens, Herman ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; HUMAN; PREVALENCE; REVIEW; UNITED STATES;

EID: 0033373186     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199912000-00002     Document Type: Review

References (45)

1. 1 Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157-161.
2. 2 Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1:57-58.
3. 3 Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998; 19:539-545. A very interesting review article, with recent data on the spread of VRE in hospitals in the USA, both in intensive care and non-intensive care units, discussing why VRE may have emerged as a nosocomial pathogen in hospitals in the USA.
4. 4 Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997; 24:545-556.
5. 5 Perichon A, Reynolds P, Courvalin P. VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother 1997; 41:2016-2018.
6. 6 Fines M, Perichon B, Reynolds P, Sahm D, Courvalin P. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother 1999; 43:2161-2164.
7. 7 Arthur M, Reynolds P, Depardieu F, Evers S, Dutka-Malen S, Quintiliani Jr, Courvalin P. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996; 32:11-16.
8. 8 Morris JG, Shay DK, Hebden JN, McCarter RJ Jr., Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995; 123:250-259.
9. 9 Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996; 23:1020-1025.
10. 10 Wells CL, Juni BA, Cameron SB. Stool carriage, clinical isolation and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21:45-50.
11. 11 Gordts B, Van Landuyt H, Ieven M, Vandamme P, Goossens H. Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. J Clin Microbiol 1995; 33:2842-2846.
12. 12 Ieven M, Vercauteren E, Descheemaeker P, Van Laer F, Goossens H. Comparison of direct plating and broth enrichment culture for the detection of intestinal colonization by glycopeptide-resistant enterococi among hospitalized patients. J Clin Microbiol 1999; 37:1436-1440. These investigators have evaluated enrichment versus direct plating of stool specimens and rectal swabs for the detection of VRE. Enrichment and stool specimens were clearly more sensitive. These results may explain some of the differences observed between Europe and the USA. In the latter enrichment is seldom used.
13. 13 Boisivon A, Thibault M, Leclercq R. Colonization by vancomycin-resistant enterococci of the intestinal tract of patients in intensive care units from French general hospitals. Clin Microbiol Infect 1996; 3:175-179.
14. 14 Klare I, Heier H, Claus H, Böhme G, Marin S, Seltmann G, et al. Enterococcus faecium strains with vanA mediated high level resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microb Drug Res 1995; 1:65-272.
15. 15 Reinert RR, Conrads G, Schlaeger JJ, Werner G, Witte W, Lütticken R, Klare I. Survey of antibiotic resistance among enterococci in North Rhine-Westphalia, Germany. J Clin Microbiol 1999; 37:1638-1641.
16. 16 McCarthy L, Gopal Rao G, Lorek A, Aylott C, Beddoe R, Ojo F, Jeanes A. Outbreak of glycopeptide-resistant Enterococcus faecium in a neonatal unit. Clin Microbiol Infect 1999; 5:103-104.
17. 17 Jordens JZ, Bates J, Griffiths DT. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1994; 34:515-528.
18. 18 Endtz HP, van den Braak N, van Belkum A, Kluytmans AJW, Koeleman JGM, Spanjaard M, et al. Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in the Netherlands. J Clin Microbiol 1997; 35:3026-3031.
19. 19 Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 1996; 40:2605-2609.
20. 20 Silverman J, Thal LA, Perri MB, Bostic G, Zervos MJ. Epidemiologic evaluation of antimicrobial resistance in community-acquired enterococci. J Clin Microbiol 1998; 36:830-832.
21. 21 Butaye P, Devriese L, Haesebrouck F. Glycopeptide resistance in Enterococcus faecium strains from animals and humans. Rev Med Microbiol 1999; 10:235-243. A very well documented review on the possible spread of VRE and vancomycin resistance genes from animals to humans.
22. 22 Thal LA, Chow JW, Mahayni R Characterization of antimicrobial resistance in enterococci of animal origin. Antimicrob Agents Chemother 1995; 39:2112-2115.
23. 23 Butaye P, Devriese LA, Goossens H, Ieven M, Haesebrouck F. Enterococci with acquired vancomycin resistance in pigs and chickens of different age groups. Antimicrob Agents Chemother 1999; 43:365-366.
24. 24 Bager F, Aarestrup FM, Madsen M, Wegener F. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microb Drug Res 1999; 5:53-56. In this study, the investigators studied the prevalence of VRE in broilers after the ban of avoparcin as a growth promotor in these food animals in Denmark.
25. 25 Kruse H, Johansen BK, Rorvik LM, Schaller G. The use of avoparcin as a growth promotor and the occurrence of vancomycin-resistant Enterococcus species in Norwegian poultry and swine production. Microb Drug Res 1999; 5:135-139.
26. 26 Pantosti A, Del Grosso M, Tagliabue S, Macri A, Caprioli A. Decrease of vancomycin-resistant enterococci in poultry meat after avoparcin ban. Lancet 1999; 354:741-742.
27. 27 Van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996; 173:1129-1136.
28. 28 Boyle JF, Soumakis SA, Rendo A, Herrington JA, Gianarkis DG, Thurberg BE, Painter BG. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31:1280-1285.
29. 29 Iwen PC, Kelly DM, Linder J, Hinrichs SH, Dominguez EA, Rupp ME, Patil KD. Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period. Antimicrob Agents Chemother 1997; 41:494-495.
30. 30 Schouten MA, Voss A, Hoogkamp-Korstanje AA. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. Antimicrob Agents Chemother 1999; 43:2542-2546. A recent and comprehensive study on the susceptibility of a large number of enterococci collected in 27 European countries.
31. 31 Vandamme P, Vercauteren E, Lammens C, Pensart N, Ieven M, Pot B, et al. Survey of enterococcal susceptibility patterns in Belgium. J Clin Microbiol 1996; 34:2572-2576.
32. 32 Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from US hospitals. Antimicrob Agents Chemother 1993; 37:2311-2317.
33. 33 Eliopoulos GM, Wennersten CB, Gold HS, Schulin T, Souli M, Farris MG, et al. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother 1998; 42:1088-1091. A recent and comprehensive study on the susceptibility of a large number of VRE collected in the USA.
34. 34 Descheemaeker P, Chapelle S, Devriese LA, Butaye P, Vandamme P, Goossens H. Comparison of glycopeptide-resistant Enterococcus faecium isolates and glycopeptide resistance genes of human and animal origins. Antimicrob Agents Chemother 1999; 43:2032-2037. This study investigates a very large collection of vanA carrying VRE isolated from humans and food animals. On the basis of the in-vitro susceptibility, pulsed-field gel electropheresis patterns and organization of their Tn1546 or related elements, the authors concluded that human and animal VRE are comparable.
35. 35 Myazaki S, Ishii Y, Ohno A, Furuya N, Matsumoto T, Tateda K, Yamaguchi K. In-vitro activities of 11 antibiotics against vancomycin-resistant enterococci isolated in Japan. J Antimicrob Agents 1999; 44:415-420.
36. 36 Ike Y, Tanimoto K, Ozawa Y, Nomura T, Fujimoto S, Tomita H. Vancomycin-resistant enterococci in imported chickens in Japan. Lancet 1999; 353:1854-1855.
37. 37 Trick WE, Kuehnert MJ, Quirk SB, Arduino MJ, Aguero SM, Carson LA, et al. Regional dissemination of vancomycin-resistant enterococci resulting from interfacility transfer of colonized patients. J Infect Dis 1999; 180:391-396. These investigators determined the prevalence and risk factors for colonization with VRE strains at 32 healthcare facilities in the USA. The data suggest that VRE emerged at these facilities among patients with long hospital stays and a history of antimicrobial use. This study provides further evidence of the differences in the epidemiology of VRE between Europe and the USA.
38. 38 Kim W, Weinstein RA, Hayden MK. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. J Infect Dis 1999; 179:163-171. This study evaluates the contributions of clonal spread, the transfer of genetic elements, and the introduction of new strains to the establishment of endemicity of VRE in one hospital. Shift from monoclonality to polyclonality was observed, which may be illustrative of the emergence of VRE in hospitals in the USA.
39. 39 Bonten MJM, Hayden MK, Nathan C, van Voorhis J, Matushek M, Slaughter S, et al. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996; 348:1615-1619.
40. 40 Mato R, De Lencastre H, Roberts RB, Tomasz A. Multiplicity of genetic backgrounds among vancomycin-resistant Enterococcus faecium isolates recovered from an outbreak in a New York City hospital. Microb Drug Res 1996; 2:309-317.
41. 41 Rao GG, Ojo F, Kolokithas D. Vancomycin-resistant Gram-positive cocci: risk factors for faecal carriage. J Hosp Infect 1997; 35:63-69.
42. 42 Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20:1126-1133.
43. 43 Pegues DA, Pegues CF, Hibberd PL, Ford DS, Hooper DC. Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital. J Clin Microbiol 1997; 35:1565-1570.
44. 44 Bingen EH, Denamur E, Lambert-Zechovsky NJ, Elion J. Evidence for genetic unrelatedness of nosocomial outbreak of vancomycin-resistant Enterococcus faecium strains in a pediatric hospital. J Clin Microbiol 1991; 29:1888-1892.
45. 45 Fridkin SK, Ykoe DS, Whitney CG, Onderdonk A, Hooper D. Epidemiology of a dominant clonal strain of vancomycin-resistant Enterococcus faecium at separate hospitals in Boston Massachusetts. J Clin Microbiol 1998; 36:965-970.